Literature DB >> 12616324

Should high hTg levels in the absence of iodine uptake be treated?

K E Britton, R R Foley, S L Chew.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12616324     DOI： 10.1007/s00259-003-1139-8

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  10 in total

1.  123I: almost a designer radioiodine for thyroid scanning.

Authors:  Hee-Myung Park
Journal:  J Nucl Med       Date:  2002-01       Impact factor: 10.057

2.  123 I as a diagnostic tracer in the management of thyroid cancer.

Authors:  J E Kalinyak
Journal:  Nucl Med Commun       Date:  2002-06       Impact factor: 1.690

3.  Should high hTg levels in the absence of iodine uptake be treated?

Authors:  Peter Lind
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01       Impact factor: 9.236

4.  Should high hTg levels in the absence of iodine uptake be treated?

Authors:  M Biermann; O Schober
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01       Impact factor: 9.236

5.  Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer.

Authors:  Lalitha K Shankar; Alvin J Yamamoto; Abass Alavi; Susan J Mandel
Journal:  J Nucl Med       Date:  2002-01       Impact factor: 10.057

6.  Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma.

Authors:  F A Leger; M Izembart; F Dagousset; L Barritault; G Baillet; A Chevalier; J Clerc
Journal:  Eur J Nucl Med       Date:  1998-03

Review 7.  Radioimmunoscintigraphy in tumour identification.

Authors:  K E Britton; M Granowska
Journal:  Cancer Surv       Date:  1987

8.  Comparison of (123)I and (131)I for whole-body imaging in thyroid cancer.

Authors:  Salil D Sarkar; Tomy P Kalapparambath; Christopher J Palestro
Journal:  J Nucl Med       Date:  2002-05       Impact factor: 10.057

9.  Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.

Authors:  Z Gulzar; S Jana; I Young; P Bukberg; V Yen; S Naddaf; H M Abdel-Dayem
Journal:  Endocr Pract       Date:  2001 Jul-Aug       Impact factor: 3.443

10.  The role of 123I-diagnostic imaging in the follow-up of patients with differentiated thyroid carcinoma as compared to 131I-scanning: avoidance of negative therapeutic uptake due to stunning.

Authors:  A Siddiqi; R R Foley; K E Britton; A Sibtain; P N Plowman; A B Grossman; J P Monson; G M Besser
Journal:  Clin Endocrinol (Oxf)       Date:  2001-10       Impact factor: 3.478
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.